Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030 - Top-Institutions - MDSpire

Strategies for Late-Phase Development to Address the Challenges of PD-1/PD-L1 Therapy: A Pathway Toward 2030

  • By

  • Elena A. Andresyuk

  • Natalya O. Porozova

  • Georgii D. Londaridze

  • Ivan S. Moiseev

  • Polina V. Kotselyabina

  • Yuri B. Porozov

  • July 20, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Columbia University Medical Center
    Columbia University Medical Center

    New York, NY

    Key Differentiators

    • Oncology

  • #3

    University of Milan
    University of Milan

    Milan, Italy

    Key Differentiators

    • Oncology

  • #4

    European Institute of Oncology
    European Institute of Oncology

    Milan, Italy

    Key Differentiators

    • Oncology

  • #5

    The University of Texas M.D. Anderson Cancer Center
    The University of Texas M.D. Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

Original Source(s)

Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030

  • by Elena A. Andresyuk, Natalya O. Porozova, Georgii D. Londaridze, Ivan S. Moiseev, Polina V. Kotselyabina, Yuri B. Porozov

  • July 20, 2026

Related Content

Radiomics and clinical data predict pseudoprogression after radiotherapy in high-grade glioma

Case Report: Chronic myeloid leukemia masquerading as essential thrombocythemia in a child: the imperative for early BCR::ABL1 testing in isolated thrombocytosis

Lipid metabolic plasticity in glioblastoma: mechanisms, tumor microenvironment remodeling, and therapeutic opportunities